This guide is designed to assist health professionals in evaluating medical and dental considerations for treating people with HIV in the era of ART. Oral health professionals play a critical role in...
This chart was developed to facilitate continuity of care for people living with HIV who may receive care in both the United States and Mexico. While most HIV medications are now available in both cou...
Colorado AETC of the Mountain West AETC has updated their tri-fold reference guide of current HIV medications. Included are infrequently used medications and formulations.
To order copies call Colorado...
Northeast/Caribbean (NECA) AETC offers online continuing education accredited videos and monographs. Here you can watch NECA AETC lectures, complete self-study modules, and earn continuing education c...
This glossary of HIV/AIDS-related terms includes brief lay-oriented descriptions and illustrations. Materials are in the public domain and may be used freely. The glossary and images are also availabl...
Colorado AETC of the Mountain West AETC has updated its HIV medication chart for providers and patients. This resource features all currently approved antiretroviral drugs and is available as a pad wi...
Each year HRSA's HIV/AIDS Bureau sponsors a conference for Ryan White Program clinicians to learn about advances in care and treatment. The AETC National Coordinating Resource Center and its partner,...
The National HIV Curriculum (NHC) provides free, up-to-date content for clinicians to learn about HIV diagnosis, treatment, and prevention. The 37 lessons and corresponding question bank topics offer...
SAMHSA provides resources related to Medication-Assisted Treatment (MAT) for the treatment of substance use disorders. MAT is the use of medications, in combination with counseling and behavioral the...
AETC HIV and Aging Workgroup
HIV and Aging Toolkit
The infographic outlines the purpose and methodology for integrating HIV care into interprofessional education (IPE) and identifies how the AETC Program is helping to facilitate this training through...
There was a pharmacokinetic study presented at the Conference on Retroviruses and Opportunistic Infections in Boston in February. It evaluated concentrations of tenofovir (TFV) and TFV-diphosphate (DP) in genital and rectal tissue. Also in anogenital fluid samples after administration of oral tenofo...
Researchers at the 2016 Conference on Retroviruses and Opportunistic Infections presented results from a randomized double-blind, double-dummy switch study of TAF/FTC. Over 660 patients with virologic suppression on TDF/FTC-containing 3-drug regimens were either switched to TAF/FTC (200/10 mg with b...
Three studies presented at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) explored the pharmacokinetics of antiretrovirals administered during pregnancy. These studies support the use of standard-dose efavirenz, once-daily dolutegravir, and BID ritonavir-boosted darunavir du...
Bictegravir (BIC) is an investigational integrase inhibitor that is being studied as part of a coformulation with tenofovir alafenamide (TAF) and emtricitabine (FTC). Two Phase 3 trials comparing a single-tablet regimen of BIC/TAF/FTC (50/25/200 mg) with regimens containing dolutegravir (DTG) plus 2...
The EMERALD Study is a Phase 3 randomized (2:1), open-label, noninferiority study examining the strategy of switching patients with suppressed HIV RNA on a regimen consisting of a boosted protease inhibitor plus tenofovir disoproxil fumarate (TDF)/emtricitabine to an investigational single-tablet re...
Doravirine (DOR) is an investigational NNRTI that currently is being developed in a coformulation with TDF and FTC. A Phase 3 comparison of DOR + 2 NRTIs (87% of study subjects were given TDF/FTC) and DRV/r + 2 NRTIs in initial therapy was presented at CROI earlier this year (DRIVE-FORWARD); the DOR...
Treatment of tuberculosis (TB) in HIV-infected persons remains challenging, in part because of drug interactions between rifampin and some ARVs that may compromise antiretroviral therapy (ART). Three studies presented at CROI provide clinicians with additional guidance on how to manage certain inter...
The U.S. Food and Drug Administration has approved the NNRTI doravirine for use in initial HIV therapy. FDA approval was based on 48-week results of 2 Phase III studies in treatment-naive persons that showed doravirine + 2 NRTIs resulted in similar rates of viral suppression at 48 weeks as either ef...
At CROI 2019, investigators presented 48-week results from the Phase 3 international multisite ATLAS and FLAIR studies of long-acting 2-drug injectable therapy. The study regimen consisted of the integrase inhibitor cabotegravir (CAB) plus the NNRTI rilpivirine (RPV), both given every 4 weeks as int...
Pharmacists have been identified by the CDC as key professionals in achieving one of the CDC’s goals of Ending the HIV Epidemic in the U.S. by preventing HIV infection. Below are some of the most common questions received at the AETC National Clinician Consultation Center (NCCC) from pharmacists abo...
